Arseus 1st quarter 2009 & outlook for 2009 Turn over growts of 12,6 % Management expects a turnover growth of between 5% and 10%. The recurring EBITDA.

Presentatie over: "Arseus 1st quarter 2009 & outlook for 2009 Turn over growts of 12,6 % Management expects a turnover growth of between 5% and 10%. The recurring EBITDA."— Transcript van de presentatie:

1 Arseus 1st quarter 2009 & outlook for 2009 Turn over growts of 12,6 % Management expects a turnover growth of between 5% and 10%. The recurring EBITDA is expected to grow faster than the turnover

2 Arseus FAGRONNO. 1 Europe 1 bln. Market DentalNO. 2 Europe 2.5 bln. Market MedicalNO. 2 Benelux CorilusNO. 1 Belgium

3 Arseus Fagron 1qrt 2009 Turnover: 34,7 M + 10,9 % Waarvan organische groei 1,5 % (in maart : 5,8 %) * FY 2008 :136,9 M

4 Arseus Dental 1qrt 2009 Turnover :37,9 M (31,3 M 2007) *+ 21,1 % (waarvan 3,6 % organische groei) * FY 2008 : 144,2 M

5 Arseus Medical 1qrt 2009 Turnover :10,5 M (11,2 M 2007) *- 6,2 % % Reason: Fall back: 3 shifts of major projects Solution: further reinforcement productfolio, operational excellence, verbetering customer service,,, * FY 2008 : 47,23 M

6 Arseus Corilus 1qrt 2009 Turnover :7 M (6,2 M 2007) *+ 12,9 % 1 or 2 position in any segment of professional medication Complete IT concepts for medical profession * FY 2008 : 26,2 M

7 Arseus 1qrt 2009 Arseus 2 years weekly

8 Arseus Aankoopkoers 800 st à 6,33 € + 5,6 % Huidige koers : 6,65 € Fundamenteel stabiel bedrijf Good management Innovatief Pharmaceutisch : defensief aandeel Technisch: stijging ingezet sinds einde maart: wordt bevestigd Conclusie : houden voor langere termijn